New antibody BT02 takes on Hard-to-Treat blood cancers
Disease control
Not yet recruiting
This early-phase trial tests a new drug called BT02, a monoclonal antibody, in 116 adults with relapsed or refractory blood cancers like leukemia, lymphoma, or multiple myeloma. Participants receive the drug by IV every 2-3 weeks for up to two years. The main goals are to check s…
Phase: PHASE1, PHASE2 • Sponsor: Biotroy Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 17:49 UTC